Cancer Hijacks Enzyme Substrate Mutations to Facilitate Tumorigenesis
癌症劫持酶底物突变促进肿瘤发生
基本信息
- 批准号:10557137
- 负责人:
- 金额:$ 21.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AffectAgonistAlgorithmsAnimal ModelAutomobile DrivingBRAF geneBiological MarkersBypassCancer Cell GrowthCancerousCell Culture TechniquesCellsClinicalCodeColon CarcinomaColonic NeoplasmsColorectal CancerComprehensive Cancer CenterDataDatabasesDiseaseDrug TargetingDrug resistanceEnzymesEpidermal Growth Factor ReceptorEsophageal carcinomaEventFRAP1 geneGRK6 geneGene AmplificationGrowthImmune checkpoint inhibitorIn VitroJointsKDR geneLifeMalignant NeoplasmsModelingMolecularMutateMutationNF1 geneNeoplasm MetastasisOncogenicPIK3CA genePTEN genePhosphorylationPhosphotransferasesPre-Clinical ModelResearchRoleSelection for TreatmentsSignal PathwaySignal TransductionSomatic MutationSpliced GenesSurvival RateTSC1/2 geneTestingThe Cancer Genome AtlasTherapeuticTimeTumor BiologyTumor PromotionTumor Suppressor ProteinsTumorigenicityXenograft procedurebeta-Transducin Repeat-Containing Proteinsbiomarker discoverycancer cellcancer therapycell growthcell typecolon cancer patientscolon cancer treatmentenzyme substrategenetic informationimprovedin vivoinhibitorinsightinterestmolecular sequence databasemouse modelmutantneglectnovelnovel therapeuticspatient stratificationpre-clinicalprecision medicineprogramsprotein kinase A kinasesmall moleculetargeted treatmenttherapeutic targettranscriptometranscriptome sequencingtumortumor growthtumorigenesisubiquitin-protein ligase
项目摘要
PROJECT ABSTRACT
Genetic information codes for life events including disease associated changes and hints for cancer treatments.
A daunting task is to decode genetic information. A common approach is to investigate whether genetic changes
in cancer are associated with tumorigenesis. Efforts have been devoted to identifying key gene
amplification/deletion/fusion events and elucidating hot mutation-associated enzymatic changes and interactome
changes. However, mutations on enzymes only account for a small portion of total mutational landscape and
meanings of the majority of non-enzyme mutations remain unclear. To this end, we have developed an algorithm
to mine the gain or loss of key enzyme substrate motifs targeting the understudied non-enzyme mutations from
TCGA database, through which key enzyme functions can be altered. As a proof-of-principle study, using this
approach we have identified 1,792 mutations in cancer that a new motif for the AGC kinases is lost. These
mutations are more enriched in colon and esophageal carcinoma to more likely affect cellular signaling pathways.
More importantly, we validated that one hit, BUD13, upon mutation can bypass its phosphorylation by one AGC
kinase GRK6, through which these cancerous BUD13 mutations deficient in phosphorylation gain oncogenicity
to promote colon cancer growth through elevating the mTORC1 signaling. In this proposal, we will systematically
identify the first mutational landscape for all characterized enzyme motifs and further validate important hits using
an experimental pipeline that we have expertise on. We will also examine new therapeutic directions associated
with both WT- and mutant-BUD13 expressing colon cancer in both in vitro cell culture models and in vivo
preclinical animal models. We hope that our study will provide novel insights for mutations cancer hijacks to
promote tumorigenesis with the potential for patient stratification and cancer treatment.
项目摘要
遗传信息编码生活事件,包括疾病相关的变化和癌症治疗的提示。
一项艰巨的任务是解码遗传信息。一种常见的方法是调查基因变化是否
与肿瘤发生有关。已经致力于确定关键基因
扩增/缺失/融合事件和阐明热突变相关的酶变化和相互作用组
变化然而,酶上的突变仅占总突变景观的一小部分,
大多数非酶突变的含义仍然不清楚。为此,我们开发了一种算法,
为了挖掘靶向未充分研究的非酶突变的关键酶底物基序的获得或丢失,
TCGA数据库,通过它可以改变关键酶的功能。作为一项原理性研究,使用
我们已经在癌症中鉴定了1,792个突变,这些突变导致AGC激酶的新基序丢失。这些
突变在结肠癌和食管癌中更丰富,更可能影响细胞信号传导途径。
更重要的是,我们验证了突变后的一个命中BUD 13可以通过一个AGC绕过其磷酸化。
激酶GRK 6,这些磷酸化缺陷的癌性BUD 13突变通过激酶GRK 6获得致癌性
通过提高mTORC 1信号来促进结肠癌的生长。在这份提案中,我们将系统地
鉴定所有表征的酶基序的第一个突变景观,并使用
一个实验管道,我们有专业知识。我们还将研究新的治疗方向相关
在体外细胞培养模型和体内细胞培养模型中,
临床前动物模型。我们希望我们的研究将为突变癌症劫持提供新的见解,
促进肿瘤发生,具有患者分层和癌症治疗的潜力。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Somatic gain-of-function mutations in BUD13 promote oncogenesis by disrupting Fbw7 function.
- DOI:10.1084/jem.20222056
- 发表时间:2023-10-02
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pengda Liu其他文献
Pengda Liu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pengda Liu', 18)}}的其他基金
Cancer Hijacks Enzyme Substrate Mutations to Facilitate Tumorigenesis
癌症劫持酶底物突变促进肿瘤发生
- 批准号:
10435664 - 财政年份:2022
- 资助金额:
$ 21.37万 - 项目类别:
Elucidating novel functions of cGAS in breast cancer
阐明 cGAS 在乳腺癌中的新功能
- 批准号:
10437847 - 财政年份:2020
- 资助金额:
$ 21.37万 - 项目类别:
Elucidating novel functions of cGAS in breast cancer
阐明 cGAS 在乳腺癌中的新功能
- 批准号:
10212348 - 财政年份:2020
- 资助金额:
$ 21.37万 - 项目类别:
Elucidating a Novel Akt Activation Mechanism for Targeted Prostate Cancer Therapy
阐明前列腺癌靶向治疗的新型 Akt 激活机制
- 批准号:
8765898 - 财政年份:2014
- 资助金额:
$ 21.37万 - 项目类别:
Elucidating a Novel Akt Activation Mechanism for Targeted Prostate Cancer Therapy
阐明前列腺癌靶向治疗的新型 Akt 激活机制
- 批准号:
9231531 - 财政年份:2014
- 资助金额:
$ 21.37万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 21.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 21.37万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 21.37万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 21.37万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 21.37万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 21.37万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 21.37万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 21.37万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 21.37万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 21.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)